130 related articles for article (PubMed ID: 34115902)
1. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth.
Wu JH; Limmer AL; Narayanan D; Doan HQ; Simonette RA; Rady PL; Tyring SK
Clin Exp Dermatol; 2021 Dec; 46(8):1551-1554. PubMed ID: 34115902
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Fang B; Kannan A; Zhao S; Nguyen QH; Ejadi S; Yamamoto M; Camilo Barreto J; Zhao H; Gao L
Sci Rep; 2020 Jun; 10(1):8867. PubMed ID: 32483262
[TBL] [Abstract][Full Text] [Related]
3. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
Iwasaki T; Matsushita M; Nonaka D; Kuwamoto S; Kato M; Murakami I; Nagata K; Nakajima H; Sano S; Hayashi K
Hum Pathol; 2015 Feb; 46(2):210-6. PubMed ID: 25466966
[TBL] [Abstract][Full Text] [Related]
5. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
[TBL] [Abstract][Full Text] [Related]
6. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma.
Lin Z; McDermott A; Shao L; Kannan A; Morgan M; Stack BC; Moreno M; Davis DA; Cornelius LA; Gao L
Cancer Lett; 2014 Mar; 344(2):272-281. PubMed ID: 24262658
[TBL] [Abstract][Full Text] [Related]
7. The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results.
Gambichler T; Majchrzak-Stiller B; Peters I; Becker JC; Strotmann J; Abu Rached N; Müller T; Uhl W; Buchholz M; Braumann C
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10831-10840. PubMed ID: 37311987
[TBL] [Abstract][Full Text] [Related]
8. Activation of the PI3K/AKT pathway in Merkel cell carcinoma.
Hafner C; Houben R; Baeurle A; Ritter C; Schrama D; Landthaler M; Becker JC
PLoS One; 2012; 7(2):e31255. PubMed ID: 22363598
[TBL] [Abstract][Full Text] [Related]
9. Probing the PI3K/Akt/mTor pathway using
Phyu SM; Tseng CC; Fleming IN; Smith TA
Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
[TBL] [Abstract][Full Text] [Related]
10. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
11. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
Arceci RJ; Allen CE; Dunkel IJ; Jacobsen E; Whitlock J; Vassallo R; Morris SR; Portnoy A; Reedy BA; Smith DA; Noble R; Murnane A; Cornfeld M; Rodriguez-Galindo C; Heaney ML; McClain K; Vaiselbuh S
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27804235
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Inhibition of Serine Palmitoyl Transferase and Sphingosine Kinase-1/-2 Inhibits Merkel Cell Carcinoma Cell Proliferation.
Bhat VK; Bernhart E; Plastira I; Fan K; Ghaffari-Tabrizi-Wizsy N; Wadsack C; Rechberger G; Eichmann T; Asslaber M; Spassova I; Verhaegen ME; Malle E; Becker JC; Sattler W
J Invest Dermatol; 2019 Apr; 139(4):807-817. PubMed ID: 30399362
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth.
Houben R; Hesbacher S; Sarma B; Schulte C; Sarosi EM; Popp S; Adam C; Kervarrec T; Schrama D
Cancer Lett; 2022 Jan; 524():259-267. PubMed ID: 34715251
[TBL] [Abstract][Full Text] [Related]
14. Mechanical regulation of glycogen synthase kinase 3β (GSK3β) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein.
Case N; Thomas J; Sen B; Styner M; Xie Z; Galior K; Rubin J
J Biol Chem; 2011 Nov; 286(45):39450-6. PubMed ID: 21956113
[TBL] [Abstract][Full Text] [Related]
15. Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation.
Lee CJ; Jang JH; Lee JY; Lee MH; Li Y; Ryu HW; Choi KI; Dong Z; Lee HS; Oh SR; Surh YJ; Cho YY
Carcinogenesis; 2015 Oct; 36(10):1223-34. PubMed ID: 26243309
[TBL] [Abstract][Full Text] [Related]
16. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.
Krasagakis K; Fragiadaki I; Metaxari M; Krüger-Krasagakis S; Tzanakakis GN; Stathopoulos EN; Eberle J; Tavernarakis N; Tosca AD
J Cell Physiol; 2011 Apr; 226(4):1099-109. PubMed ID: 20857409
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
18. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
19. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator.
Shuda M; Kwun HJ; Feng H; Chang Y; Moore PS
J Clin Invest; 2011 Sep; 121(9):3623-34. PubMed ID: 21841310
[TBL] [Abstract][Full Text] [Related]
20. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
